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A B S T R A C T
Well-characterized, high-quality brain tissue of non-neurological control subjects is a prerequisite to study the
healthy aging brain, and can serve as a control for the study of neurological disorders. The Normal Aging Brain
Collection Amsterdam (NABCA) provides a comprehensive collection of post-mortem (ultra-)high-field MRI
(3Tesla and 7 Tesla) and neuropathological datasets of non-neurological controls. By providing MRI within the
pipeline, NABCA uniquely stimulates translational neurosciences; from molecular and morphometric tissue
studies to the clinical setting. We describe our pipeline, including a description of our on-call autopsy team,
donor selection, in situ and ex vivo post-mortem MRI protocols, brain dissection and neuropathological diagnosis.
A demographic, radiological and pathological overview of five selected cases on all these aspects is provided.
Additionally, information is given on data management, data and tissue application procedures, including re-
view by a scientific advisory board, and setting up a material transfer agreement before distribution of tissue.
Finally, we focus on future prospects, which includes laying the foundation for a unique platform for neuroa-
natomical, histopathological and neuro-radiological education, of professionals, students and the general (lay)
audience.
1. Introduction
1.1. Purpose and mission
A deeper knowledge of the impact of neuropathology on the neu-
roanatomical circuitry in the aging human brain is required to under-
stand why some people develop highly disabling neurological condi-
tions, whereas others remain neurologically (and mentally) unimpaired
until the age of 100 years or more (Ailshire et al., 2015). Well-char-
acterized, high-quality brain tissue of non-neurological control subjects
is a prerequisite to study the healthy aging brain, and can serve as a
control for the study of neurological disorders. Nevertheless, high-
quality post-mortem brain tissue samples of controls without
neurological or mental disorders are sparse. To combine willed body
donation for medical education and brain donation for research with
the same donor, is an efficient opportunity to address both (education
and research) needs. Although research groups have included post-
mortem MRI in their studies, most notable in the case of patient H.M.
(Augustinack et al., 2014), to our knowledge, none of the brain banks
worldwide have high-field, whole-brain post-mortem in situ magnetic
resonance imaging (MRI) data in combination with high quality brain
tissue available for scientific research (Daniel and Lees, 1993; Freund
et al., 2018; Friedman et al., 2017; Grinberg et al., 2007; Haroutunian
and Pickett, 2007; Newcombe and Cuzner, 1993; Rademaker et al.,
2018; Ramirez et al., 2018; Ravid and Swaab, 1993; Smith and Millar,
2018; Sutherland et al., 2016; Vonsattel et al., 2008).
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The Normal Aging Brain Collection Amsterdam (NABCA) answers to
this need by providing a comprehensive collection of post-mortem
(ultra-)high-field MRI (3Tesla and 7 Tesla) and neuropathological da-
tasets of non-neurological controls. By direct coupling of postmortem
MRI and tissue as intrinsic elements of the NABCA collection, we aim to
provide the scientific community with a means to translate molecular,
cellular, histopathological and brain imaging knowledge to the clinical
setting.
NABCA objectives can be summarized as follows:
- Provide the neuroscientific research community (worldwide) with
crucially needed, excellently documented, high-quality MRI data
and brain tissue of non-neurological controls, for studies of a wide
variety of neurological disorders;
- Lay the national foundation for studies of healthy aging, based on a
collection of stringently collected brain tissue from 18 to 90 years
old;
- Stimulate and innovate translational neurosciences (i.e., translation
from molecular and morphometric tissue studies to the clinical
setting, via advanced post-mortem MR imaging);
- Develop educational neuroanatomical, histopathological and neu-
roradiological packages for professionals, students and the general
(lay) audience.
We have developed a protocol to collect brains of non-neurological
donors with a short (4 h–12 h) post-mortem interval (PMI), in combi-
nation with uniform and comprehensive characterization with MRI, and
histopathology.
1.2. Research site, study population and ethical approval
NABCA is embedded within the department of Anatomy and
Neurosciences, Amsterdam Neuroscience, VU University medical center
(VUmc). This department has the privilege of administering the human
body bequest program. The process of accepting and managing be-
quests is governed by the human tissue act (‘ter beschikking stelling’,
Artikel 18, lid 1 en 19 van de Wet op de Lijkbezorging, 1991), which
allows body donation to facilitate medical research and education.
Donors above the age of 18 are eligible to the human body bequest
program at VUmc and approximately ~2200 donors are currently re-
gistered. In collaboration with the mortuary, NABCA includes ~10
donors a year in the rapid MRI-autopsy pipeline, based on in Section 2.2
mentioned inclusion/exclusion criteria. All medical research on human
subjects is ethically and legally guided by the Declaration of Helsinki
(https://www.wma.net/policies-post/wma-declaration-of-helsinki-
ethical-principles-for-medical-research-involving-human-subjects/).
Additionally, NABCA has obtained approval of our institutional ethical
review board for all aspects of the pipeline.
2. Autopsy pipeline
Various autopsy pipelines have previously been described (e.g.Beach
et al., 2015; Bell et al., 2008; Samarasekera et al., 2013). However,
NABCA has developed a pipeline that includes in situ 3 T and ex vivo 7 T
MRI as standard practice (see Fig. 1 for an overview). In brief, it starts
with donor selection for post-mortem in situ 3 T MRI based on age,
cause of death and post-mortem delay. The 3 T MRI is evaluated by a
neuroradiologist for radiological abnormalities suggestive of neurolo-
gical disease. After MRI, craniotomy takes place and the brain is pho-
tographed and evaluated by a neuropathologist, the weight is noted and
fresh snap-frozen tissue excision is performed on the left hemisphere
based on an extensive standardized protocol. The right hemisphere is
placed in 4% formalin for four weeks, then ex vivo scanned at 7 T MRI,
and subsequently dissected. In total 35 formalin fixed tissue blocks are
collected and embedded in paraffin, the remaining brain tissue is kept
in formalin. Histological and immunostained sections of 15 brain
regions are evaluated for neuropathological diagnosis, all according to
strict standardized protocols in line with BrainNet Europe (BNE)
(Alafuzoff et al., 2009b; Alafuzoff et al., 2009a; Alafuzoff et al., 2008).
After in situ MRI and further brain autopsy, the body is returned to the
Anatomy and Neurosciences morgue for further enrolment in the body
donation program for education and scientific research. Since 2014,
NABCA has so far included over 40 donors. We will explain each of the
pipeline aspects in the following paragraphs.
2.1. On call MRI and autopsy teams
Previous molecular and biochemical studies using postmortem brain
tissue have indicated that post-mortem interval (PMI) has an influence
on brain tissue quality (Birdsill et al., 2011; Durrenberger et al., 2010;
Ramirez et al., 2018), it therefore is crucial to keep the time between
Fig. 1. Overview of NABCA pipeline. Starting with donor selection based on
available criteria, an in situ MRI is performed. The scan protocol includes a 3D-
T1w, PD/T2w and FLAIR sequence (a radiological report of the in situ MRI is
provided by an experienced radiologist in the days after the scan). After the in
situ MRI, craniotomy takes place at autopsy, the brain is cut in half; the left
hemisphere is dissected in ~80 tissue blocks for molecular and/or biochemical
analysis, the right hemisphere is put in 4% formalin. After four weeks, ex vivo
7 T MRI is performed on the right hemisphere. The scan protocol includes a 3D-
T1w, 3D FLAIR and T2*w sequence. Subsequently the right hemisphere is
dissected in 35 tissue blocks for paraffin embedding. Fifteen tissue blocks are
then used for a full pathological report provided by an experienced neuro-
pathologist. After this, the non-neurological data is ready for distribution after
completion of an application form, approval from the scientific advisory board
and institutional review board, and signing of a material transfer agreement
(MTA).The NABCA pipeline has been approved by local ethical committee.
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death and autopsy to a minimum. This can only be achieved by the
maintenance of a team that is readily available in case of an autopsy.
Before team members become a part of the on-call team, they are
trained by means of an extensive introduction and attending an autopsy
without assisting. Subsequently, they assist an experienced team
member and finally they will join the team as full members. Ongoing
meetings are organized to evaluate training needs of team members.
For safety and efficiency, at each callout one MRI operator and two
autopsy assistants are required. MRI operators and autopsy assistants
rotate through a weekly on-call schedule that is planned two months
ahead. The neuropathologists have their own on-call schedule at the
department of pathology in accordance to other brain banking duties.
To expedite the workflow, an autopsy kit is prepared in advance; con-
tainers and cassettes are labelled and equipment is laid out ready for
use.
2.2. Donor in/exclusion and clinical information
According to the human tissue act, the family of the deceased has up
to 24 h to release the body. NABCA only receives a notification (from
the VUmc, Anatomy and Neurosciences morgue) if the donor can be at
the VUmc morgue within seven hours after death. An exclusion cri-
terion is the cause of death being a neurological or mental disorder,
including sepsis, encephalitis, asphyxia, a cerebrovascular accident or
traumatic brain injury. Cases with a medical history of neurological or
psychiatric diagnosis are excluded too. Furthermore, NABCA focuses on
collecting donors above 18 and below 90 years of age. A last exclusion
criteria is the presence of neuropathological change at pathological
assessment, which will be discussed in Section 2.6.
2.3. Post-mortem in situ 3 T MRI and radiological assessment
When a donor has been included, first an in situ MRI (brain still in
cranium) is performed on a 3 T whole body scanner (General Electric
Signa MR750) using an eight-channel phased-array head coil. The scan
protocol (~45min) is optimized for the post-mortem setting and in-
cludes an axial 2D proton density/T2-weighted (PD/T2w) sequence for
clinical reference and pathological-anatomical differentiation, a sagittal
3D fluid attenuated inversion recovery (FLAIR) sequence to visualize
possible (vascular-ischemic) white and gray matter pathology, a sagittal
3D T1w fast spoiled gradient echo (FSPGR) sequence for gray/white
matter differentiation; enabling the study of regional volumes, cortical
thickness and shapes, a susceptibility-weighted (T2*w) sequence for
iron deposits and microbleeds, and an axial 2D diffusion tensor imaging
(DTI; separate reference images with reversed phase encoding direc-
tions to estimate and correct susceptibility induced distortions) se-
quence for microstructural analysis and structural connectivity. See
Table 1 for sequence details and Fig. 2 for an example of images. Aside
from general post-mortem optimizations, the FLAIR contrast depends
on optimal suppression of CSF. However, due to differences in post-
mortem delay and brain temperature, T1 relaxation times differ.
Therefore, we measure a short series of FLAIR images with low spatial
resolution to determine the optimal inversion time per case.
Independent from the autopsy (often the following day), the MRI
examination is assessed by an experienced neuroradiologist. The radi-
ological report includes presence of space occupying lesions or other
focal/unexpected findings and assessment of atrophy; both global (scale
0–3) and local (scale 0–4), severity of white matter hyperintensities
(Fazekas scale 0–3), number of (basal ganglia) lacunar and other in-
farctions (Fazekas et al., 1987; Wardlaw et al., 2013).
Volumetric analysis of the in situ MRI images can be done with
processing tools used in vivo, such as the FMRIB Software Library (FSL;
version 5.0) (Jenkinson et al., 2012). This includes removal of non-
brain tissue (BET) on T1-weighted images, and tissue segmentation
with SIENAX (Smith et al., 2002) from which normalized volumetric
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measured with FIRST (also part of FSL (Jenkinson et al., 2012)). See
Table 3 for the measurements of 5 non-neurological controls. These
volumetric values fall within the range indicative for normal aging in in
vivo studies (Jack et al., 2015; Scahill et al., 2003).
2.4. Post-mortem ex vivo 7 T MRI
Back in the mortuary, craniotomy takes place and the brain is dis-
sected into two halves; the left hemisphere is further dissected ac-
cording to a snap frozen protocol (see paragraph 2.5.1), the right
hemisphere is stored in 4% formalin.
A higher spatial resolution and signal to noise ratio can be achieved
at higher field strengths and longer acquisition times. In addition, 7 T
MRI provides unique image contrast compared to the conventional 3 T
MRI, particularly for susceptibility-weighted contrast (T2⁎w or SWI).
These susceptibility-weighted changes are closely related to myelin and
iron allowing detection of cortical lamination and iron-associated
pathology (Bulk et al., 2018; Nabuurs et al., 2010; van Rooden et al.,
2009). Therefore, we include an ex vivo 7 T MRI scan, performed at
LUMC (Leiden, the Netherlands) on a whole-body human 7 T MR
system (Philips Healthcare, Best, the Netherlands) After four weeks of
formalin fixation, the right hemisphere is rinsed with tap water for 24 h
to partially restore the relaxation parameters (Shepherd et al., 2009).
The hemisphere is subsequently sent to LUMC in Phosphate-buffered
saline (PBS) and there placed in a plastic bag containing a proton-free
fluid (Fomblin®, LC08, Solvay). To minimize the amount of trapped air
bubbles, a vacuum is applied overnight. Before scanning, the plastic bag
is sealed and fixed on a plastic plateau in the center of the quadrature
transmit and 32-channel receiver head coil. The scan protocol (~8 h)
includes a coronal 3D T1w scan, and a sagittal 3D FLAIR. Several T2⁎w
sequences are included with resolutions ranging from lower
(0.6× 0.6× 0.6mm) to higher (0.3× 0.3× 0.3mm). We acquired ex
vivo data at different resolutions in order to bridge the gap between ex
vivo and in vivoMRI. Ex vivoMRI allows resolutions around 200 um due
Fig. 2. Overview of images included in the NABCA in situ pipeline. Images A-H are from NABCA case 1, age 68, showing no pathological abnormalities, image I is
from NABCA case 5, age 59, showing no pathological abnormalities (see Table 3). A-C: sagittal 3D T1w image and reconstructed coronal and axial views, D-F: sagittal
3D FLAIR image and reconstructed coronal and axial views, G: axial 2D proton density (PD) image, H: corresponding axial 2D T2-w image, and I: axial 2D
Susceptibility Weighted Image (SWI).
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to ‘unlimited’ scan time, in contrast, typical high-resolution scans in vivo
are acquired at 600 um. Additionally, although fixation drains most of
the blood remaining in cerebral vessels, one needs to take into account
remaining artefacts when performing quantitative analyses of the T2*w
data. See Fig. 3 for an overview of images obtained at 7 T.
2.5. Dissection protocols
After in situ MRI, the donor is transported to the morgue and cra-
niotomy takes place. Just before brain removal, the pH of the cerebral
spinal fluid (CSF) is measured as an indicator of agonal state (Monoranu
et al., 2009). Then the brain, with cervical spinal cord, is delicately
removed from the skull by the neuropathologist. Additionally, the pi-
tuitary gland is dissected from the sella turcica. The brain is weighted,
carefully inspected and photographed from different angles. The au-
topsy assistants notes the neuropathologist's assessment of the brain's
external vasculature (including circle of Willis) and surfaces (e.g.
atrophy, softening). After this, the cerebellum and brainstem are re-
moved from the cerebrum at the cerebral peduncles. Upon dissection of
the brainstem, pigmentation of the substantia nigra (SN) and locus
coeruleus (LC) are assessed and noted. The two hemispheres are sub-
sequently split in two; the left hemisphere will be further dissected
according to a snap frozen (liquid nitric oxygen) protocol, the right
hemisphere will be stored in 4% formalin for four weeks and dissected
after 7 T MRI. The same is done for the cerebellum and brain stem. We
will briefly discuss both protocols in the following sections. All dis-
sections are performed by an experienced neuropathologists and any
salient details at autopsy are written down.
2.5.1. Snap frozen tissue dissection
The snap frozen tissue is stored at -80 °C and may be used for further
molecular, biochemical, genetic and cellular analysis. Dissection
protocol is based on the BrainNet Europe (BNE) protocol (http://www.
brainnet-europe.org/ under “Results”, then “Protocols”), and includes
~80 tissue excisions of ~40 brain regions of the cerebrum, cerebellum
and brain stem (see supplementary Table 1). Additional to the protocol,
two tissue blocks are dissected and snap frozen, one cortical and one
cerebellar region. These will later be used to determine the RNA in-
tegrity number (RIN), as quality assessment of the frozen tissue
(Schroeder et al., 2006).
2.5.2. Formalin fixed tissue dissection
When the formalin fixed right hemisphere is returned from 7 T MRI
scanning, the hemisphere is rinsed to dispose of any Fomblin that may
still be present. The meninges are carefully removed and the hemi-
sphere is assessed and photographed from all directions with a ruler
(any salient details are written down). A coronal cut is made caudal of
the anterior commissure, then slices of 0.5 cm thickness are made in
both directions (Fig. 4). The formalin fixed dissection protocol includes
~35 regions (see supplementary Table 2). The protocol includes regions
for pathological diagnosis (see paragraph 2.6), but is further extended
to address specific research needs from researchers requesting tissue
from NABCA. The formalin fixed dissected tissue blocks are put in
cassettes and are paraffin embedded.
2.6. Neuropathological diagnosis
The last part of the NABCA pipeline involves obtaining a neuro-
pathological diagnosis to ensure they can be considered non-neurolo-
gical (Nolan et al., 2015). An extensive pathological assessment is done
to obtain an overview of age-related or disease-related cellular changes.
From the formalin-fixed dissection, 15 regions (see supplementary
Table 3) are selected, and series of 10×6-μm-thick sections are cut and
mounted onto glass slides. These regions are then stained with
Fig. 3. Overview of sequences included in the NABCA 7 T ex vivo pipeline. Images are from NABCA case 1 (see Table 2). A sagittal 3D FLAIR. B-D T2*-weighted scans
at different resolutions. B 0.6× 0.6×0.6mm, C 0.3× 0.3×0.3mm, D 0.25× 0.25×1mm.
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(immuno)histochemistry. Manual staining is done for hematox-
ylin–eosin (HE) for gross anatomical inspection and (micro)infarctions,
Congo Red and Gallyas silver staining for plaques, tangles and other
inclusions. Automatic staining is done with Ventana Benchmark Ultra
(Roche Diagnostics, Mannheim, Germany), with prediluted primary
antibodies against hyper phosphorylated (p-)tau for aggregates (in-
cluding pretangle neurons, neurofibrillary tangles, neuritic plaques,
neuropil threads, and dystrophic neurites), α-synuclein to identify Lewy
bodies and Lewy-related neurites, Amyloid-β for amyloid deposits, TAR
DNA-binding protein 43 (TDP-43) to detect intraneuronal inclusions,
and ionized calcium-binding adapter molecule 1 (Iba1) for presence of
microglia (see Table 2 for an overview and details).
Pathological assessment is done by an experienced neuropathologist
(A.R.) who is blinded to clinical and MRI findings. With the above
mentioned staining protocol, an assessment and distinction is made
regarding AD-related pathologies, α-synuclein pathologies, TDP-43
pathology, hippocampal sclerosis, vascular pathologies and mixed
pathologies (Alafuzoff et al., 2008, 2009a, 2009b; Alafuzoff, 2018;
Monoranu et al., 2009; Nag et al., 2015). The extent of AD-related
neuropathological burden is summarized by an ‘ABC score’ according to
the 2012 NIA-AA guidelines (Hyman et al., 2012; Montine et al., 2012),
which is a composite of 3 scores: (A) stands for Amyloid plaque Thal
phase (Thal et al., 2002), (B) stands for Braak stage of NFTs (Braak and
Braak, 1991), and (C) stands for Consortium to Establish a Registry for
Alzheimer's disease (CERAD) score of neuritic plaques (Hyman et al.,
2012). Each criteria is scored on a four-point scale between 0 (no
pathology present) and 3 (highest phase/stage/score), and a combina-
tion of A, B and C scores represent a ‘not’, ‘low’, ‘intermediate’ or ‘high’
level of AD-related neuropathological change. An ‘intermediate’ or
‘high’ neuropathological change is considered indicative for AD
(Hyman et al., 2012; Montine et al., 2012). For staging and typing of
Lewy body related α-synuclein pathology, a combination of Braak
staging 1 to 6 (Braak et al., 2003) and McKeith typing of brainstem,
limbic, neocortical and amygdala-predominant categories (McKeith
et al., 2005) is applied, as proposed by BNE (Alafuzoff et al., 2009a).
Additionally, brain tissue was also inspected for other salient pathology
such as age-related tau astrogliopathy (ARTAG) (Kovacs et al., 2016),
cerebral white matter rarefactions, cerebral amyloid angiopathy (CAA)
and (micro)infarctions and hemorrhages and TDP pathology (Nag et al.,
2015).
NABCA cut-off scores for inclusion as a non-neurological control
based on pathology are an ‘not’ or ‘low’ classification of AD-related
neuropathological change (an ‘ABC score’ lower than A1 B2 C2), the
occurrence of Lewy body pathology higher than Braak stage 3 out of 6
for alphasynucelinopathy (limbic and neocortical), or other salient
pathology such as metastases and infarctions or hemorrhages.
2.7. APOE genotyping
For genotyping, 25mg of tissue is cut from snap-frozen tissue blocks
and used for DNA isolation. Frozen material is purified with the
PureLink Genomic DNA mini kit (Invitrogen, Carlsbad, California, USA)
Fig. 4. Overview of a formalin fixed right hemisphere before slice dissection (top) and after dissection into slices. Beginning at the top left, ending at bottom right are
0.5 cm consecutive slices starting at the frontal cortex and moving posteriorly.
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according to manufacturer's protocol. DNA is eluted in 100 μl H2O and
concentration and quality of eluted DNA is measured by nanodrop (ND-
1000 spectrometer, Thermo Fisher Scientific Inc., Wilmington,
Delaware, USA). Sequencing is performed using Sanger sequencing on
an ABI130XL. Subjects are classified as homo- or heterozygote APOEε2,
APOEε3 or APOEε4 carriers.
3. Overview of selected cases
To exemplify our pipeline, we have selected five NABCA cases and
have put the clinical, MRI, pathological and genotyping data together
(see Table 3). On MRI only some mild global or local hippocampal
atrophy and mild to moderate vascular white matter changes were
observed. Pathologically, the ABC score was not suggestive of Alz-
heimer pathology for any of the cases. Additionally, case 1 showed
some tauopathy in the amygdala, suggestive of ARTAG. Case 4 showed
very early stages of α-synucleinopathy (incidental Lewy body pa-
thology), but not enough for a Braak α-syn Stage 1. Case 5 showed a
few small cortical infarctions. In summary, these cases showed only
minimal age-related changes and can be considered non-neurological
controls.
4. Storage and distribution of data and tissue
4.1. Database
NABCA has developed a database and infrastructure for data man-
agement. After each autopsy, the database is updated and standardized
forms are filled in regarding autopsy details. When more information
becomes available about the clinical history, MRI report or pathological
diagnosis, this is added to the database. This way, a comprehensive and
integrated overview of demographic information (excluding any per-
sonal data of the donor), a summary of the medical history, MRI and
pathological data is available, as well as an inventory of the snap-frozen
and formalin-fixed tissue blocks that were excised. In the near future
records of (pending) tissue requests and shipments will be added.
Comprehensive search queries can generate various data reports for an
overview of available information and tissue. The database is backed up
automatically and stored on a secure server. Paper copies of dissection
records are saved in a locked filing cabinet.
Table 2
Technical details of the (immuno)histopathological staining for pathological diagnosis.
Primary Supplier Clone Dilution Antigen retrieval method
Nissl (Thionine) Thermo Fisher Scientific – – –
HE Klinipath/Q-path – – –
Congrored VWR – – –
Gallyas Merck KGaA – – –
Anti-Aβ A4 Dako 6f/3d 1:25 CC1: Ventana Benchmark Ultra
Anti-Tau Innogenetics AT8 1:10.000 CC1: Ventana Benchmark Ultra
Anti-α-Synuclein BD Biosciences 42 1:5.000 CC1: Ventana Benchmark Ultra
TDP-43 cosmobio poly 1:1000 CC1: Ventana Benchmark Ultra
Iba1 Wako Industries poly 1:4000 CC1: Ventana Benchmark Ultra
Aβ: amyloid-beta; HE: hematoxylin and eosin; Aβ: amyloid-beta; TDP: transactive response DNA-binding protein; Iba1: intracellular calcium binding protein-1; CC1:
cell conditioning 1.
Table 3
Demographics, pathological and MRI characteristics of included donors.
ID Case 1 Case 2 Case 3 Case 4 Case 5 Mean ± SD
Gender M F F F F 1M/4F
Age (y) 68 71 72 77 59 69.4 ± 5.9
PMI (h:m) 8:40 6:50 7:20 4:30 8:10 7:02 ± 1:34
pH of CSF 6.12 6.87 n/a 6.5 6.08 6.39 ± 0.32
Pathological classification “ABC score” A1 B1 C0 A1 B1 C0 A0 B0 C0 A1 B1 C0 A0 B0 C0 –
Thal phase 2 2 0 2 0 –
Braak NFT 1 0–1 0 2 0 –
Braak a-syn 0 0 0 0 0 –
TDP-43 0 0 0 0 0 –
CAA 0 0 0 0 0 –
APOE-4 E3/E4 E3/E4 E3/E3 E3/E3 E3/E3 –
MTA R/L 0/0 0/1 0/0 1/2 0/0 –
GCA 0 1 0 1 1 –
Fazekas 0 2 1 2 2 –
lacunes 0 0 0 0 0 –
BG lacunes 0 0 0 0 0 –
Infarcts 0 0 0 0 0 –
NBV (L)a 1.61 1.48 1.51 1.50 1.46 1.51 ± 0.05
NWMV (L)a 0.76 0.71 0.72 0.71 0.68 0.72 ± 0.03
NGMV (L)a 0.85 0.77 0.80 0.78 0.78 0.80 ± 0.03
Hippocampus right (ml)b 5.31 4.85 6.52 5.20 5.60 5.50 ± 0.57
Hippocampus left (ml)b 5.06 5.21 6.35 4.24 5.67 5.31 ± 0.70
M=male, F= female, PMI= post-mortem interval, CSF= cerebrospinal fluid NBV=normalized brain volume, ABC score= score for Aβ deposition (A), for Braak stage of
neurofibrillary degeneration (B) and neuritic plaque score (C), NFT= neurofibilary tangles, TDP=TAR DNA-binding protein, CAA= cerebral amyloid angiopathy,
APOE=Apolipoprotein E, GCA= global cortical atrophy,BG= basal ganglia, NWMV=normalized white matter volume in litres (L), NGMV=normalized gray matter
volume. n/a= not available.
a Normalized volumes obtained with SIENAX.
b Normalized volumes obtained with FIRST.
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4.2. Security, privacy and anonymization of data
NABCA works with linked anonymized donors, meaning, family
name or other personal data (e.g. date of birth or address) of the donor
is only available to the head of the morgue (for the human bequest
program; information stored in a locked cabinet) and never to people
working with NABCA (including CEO, coordinator and on call teams).
To NABCA donors are anonymous ID numbers with limited information
as shown in Table 3. Regarding MRI scans, brain scans are unique and
could allow for identification of the individual (BRAINS (Brain Imaging
in Normal Subjects) Expert Working Group et al., 2017), therefore
further de-identification of MRI data is applied. Image header in-
formation is removed (Rodríguez González et al., 2010), and either
defacing (Milchenko and Marcus, 2013), or brain extraction methods
(Jenkinson et al., 2012) are applied before distribution.
4.3. Website
NABCA has a website (http://nabca.eu) where contact information
and information regarding the application process can be found. In the
future, the website will also feature a list with publications that have
used NABCA MRI and/or tissue.
4.4. Distribution of data and tissue
Requests for MRI data or tissue can be done through an application
form. The application form requires information regarding general in-
formation of the applicant, content of the project (summary, back-
ground, deliverables, duration), a statement on how the project applies
to NABCA objectives, project funding source and possible collaboration
with for-profit organizations. Additionally, an overview of the re-
quested data/tissue (number of donors, age range, gender, specific MRI
sequences, specific tissue type and locations) is required. This will
briefly be reviewed by the NABCA coordinator for completeness and
general feasibility/availability. The application will then be sent to
NABCA's scientific advisory board which will assess the application
based on 1) scientific merit (design, methods, analysis). 2) If the re-
search is in line with the objectives that NABCA is pursuing (see below).
3) originality/innovation. 4) suitability of requested data/tissue (re-
gions, suitable number of donors). The Scientific Advisory Board gen-
erally responds with their advice within two weeks after the application
has been submitted. Their advice could be to grant the application,
grant the application if a few additional points are elucidated, or reject
the application in its current form. If the application is rejected, a
reason is given. After the Scientific Advisory Board, the application is
reviewed by the Institutional Review Board. If their advice is positive, a
Material Transfer Agreement (MTA) is signed by both parties, and data/
tissue is allocated. Payments are set up to cover replacing of brain tissue
with new cases, shipment and handling costs. NABCA has a not-for-
profit financial model, there is no monetary gain for staff or institute
involved.
5. Discussion, conclusions and future prospects
NABCA's vision is to create a cutting-edge repository of post-mortem
non-neurological human brain tissue and post-mortem (ultra-)high-
field MR imaging data to national and international researchers, aca-
demic and industry. This creates a foundation for the study of healthy
aging and as controls for wide variety of neurological disorders, sti-
mulating translational neurosciences, from molecule to mind.
The combination of post-mortem MRI and (immune)histopathology
has already proven its great value in the study of prevalent neurode-
generative and neuro-inflammatory diseases (Benveniste et al., 1999;
Bulk et al., 2018; Geurts et al., 2005; Gouw et al., 2008; Jonkman et al.,
2016; Jonkman and Geurts, 2018; Kilsdonk et al., 2016; Nabuurs et al.,
2013; van Veluw et al., 2013). In multiple sclerosis (MS), validation of
the pathological substrate of MRI signal changes has led to improve-
ment and implementation of new MRI sequences (Geurts et al., 2011),
which in turn helped to improve diagnostic and prognostic accuracy
(Filippi et al., 2016). In Alzheimer's disease (AD), histopathological
defined cerebral microinfarcts (CMIs) were first detected as hyper-
intense focal lesions on ex vivo 7 T MRI, then on in vivo 7 T MRI in the
same study (van Veluw et al., 2013) and subsequently on in vivo 3 T
MRI, which could be related to clinical phenotype (cognitive impair-
ment) (Ferro et al., 2017; Hilal et al., 2016). Additionally, the combi-
nation of post-mortem MRI and histology has played a crucial role in
creating and validating several (cortical and subcortical) anatomical
atlases (Adler et al., 2018; Chakravarty et al., 2006; Ewert et al., 2018;
Yelnik et al., 2007; Yushkevich et al., 2009), or software packages
(Cardinale et al., 2014). In the future, in situMRI could play an essential
role as an intermediate between ex vivo and in vivo registration and
validation (Wisse et al., 2016). Additionally, studies regarding valida-
tion of new MRI sequences and development of MRI biomarkers will
increase and continue to require post-mortem tissue validation. Lastly,
the combination of molecular/biochemical, histopathological and 3D
neuroanatomical (at macroscale and microscale) of the same donor
allows answering questions regarding impact of molecular changes or
pathological lesions on anatomical circuitry.
Nevertheless, some limitations can be mentioned about the pipeline.
Donors enrolled for NABCA, or the body bequest program in general,
may not be an accurate representation of the entire (Dutch) population.
Due to personal or religious feelings, the population may lack some
diversity. In addition, few young adult donors have been included to
date. Information regarding the medical history may be limited or
sometimes lacking (general practitioners have the right not to disclose
patients' information). The MRI sequences may be limited and not at
par to a researcher's need, but NABCA continues to develop and include
more advanced imaging techniques. Additionally, tissue quality is an
important aspect and the RNA integrity number (RIN) of all specimens
is collected. For biochemical and next-generation sequencing however
other quality measures may need to be included.
In the future NABCA would like to (i) add morphometric data to
imaging and histology, such as size, shape and distribution of neurons,
axons and pathological hallmarks. (ii) Add more genotyping data such
as amyloid precursor protein (APP), presenilin-1 (PS-1) and presenilin-2
(PS-2), leucine rich repeat kinase 2 (LRRK2), glucocerebrosidase (GBA),
synuclein alpha (SNCA) multiplication and others (Blauwendraat et al.,
2017). (iii) feed data (e.g. molecular information) from research teams
using NABCA data back into the database (iv) lay the foundation for a
unique platform for neuroanatomical, histopathological and neuror-
adiological education, of professionals, students and the general (lay)
audience. For instance by organizing (summer)courses and lectures
based on NABCA's multimodal datasets. Additionally, in the develop-
ment of new ways of visualizing brain structure, NABCA is collabor-
ating with researchers who are developing an app together with the
gaming industry, VU University Medical Center's 3D Innovation Lab
and a scientific team from Delft Technical University. This app will
feature the multimodal (MRI, anatomy and molecular data) normal
brain repository. Besides professionals and the scientific community,
the general audience is extremely interested in brain science as well
explaining the recent success of ‘brain books’ for the layperson and e.g.
outreach organizations such as ‘Brein in Beeld’ (http://breininbeeld.
org; outreach ~2500 people). The education of the scientific commu-
nity and general public alike will not only improve the general
knowledge on the aging human brain, but will also increase awareness
of the importance of studying human tissue and brain banking in gen-
eral.
In conclusion, the immense scope of modalities and techniques in-
volved (i.e. molecular, cellular, network imaging) is unprecedented and
NABCA forms a unique platform for translational neuroscience research
and education.
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